8-K: Immunocore Presents Promising Phase 1 Data for Brenetafusp in Ovarian Cancer and T Cell Fitness Biomarker

Immunocore announced positive Phase 1 clinical trial results for brenetafusp in heavily pre-treated ovarian cancer patients, both as a monotherapy and in combination with chemotherapy, and highlighted the importance of T cell fitness as a biomarker for clinical activity.

Summary

• Immunocore presented Phase 1 data for brenetafusp, an ImmTAC bispecific therapy, in patients with platinum-resistant ovarian cancer at the 2024 European Society for Medical Oncology (ESMO) Congress.
• The data showed that brenetafusp is clinically active as a monotherapy and in combination with chemotherapy in heavily pre-treated patients.
• In the monotherapy arm, 37 patients with a median of 5 prior lines of treatment were evaluated, with 58% achieving disease control and a 6.5% RECIST response rate.
• The median progression-free survival (PFS) was 3.3 months, and the overall survival (OS) was 73% at 6 months.
• A subset of 29 patients showed a 31% molecular response rate based on circulating tumor DNA (ctDNA) reduction.
• In the combination arm, 16 patients with a median of 4 prior lines of treatment were evaluated, with 69% achieving disease control and a 23% RECIST response rate.
• The molecular response rate in the combination arm was 82% in 11 evaluable patients.
• The company also presented data showing that T cell fitness (TCF) gene expression signature in blood is an important parameter associated with clinical activity for both brenetafusp and KIMMTRAK.
• Patients with a TCF signature above the median showed greater clinical activity, including higher disease control rates, longer PFS, and improved OS.

Sentiment

Score: 8

Explanation: The document presents positive clinical data for brenetafusp, particularly in combination with chemotherapy, and highlights a promising biomarker. While there are risks and uncertainties, the overall tone is optimistic and suggests potential for future success.

Positives

• Brenetafusp shows promising clinical activity in heavily pre-treated ovarian cancer patients, both as a monotherapy and in combination with chemotherapy.
• The combination therapy with brenetafusp and chemotherapy showed a higher response rate compared to historical chemotherapy data in similar patient populations.
• The identification of T cell fitness as a biomarker could help identify patients who are more likely to respond to ImmTAC therapies.
• Brenetafusp was well tolerated with no treatment-related discontinuations or deaths observed.
• The company is expanding the study of brenetafusp combinations, including in earlier-line platinum-sensitive disease.

Negatives

• Cytokine release syndrome (CRS) was observed in 57% of patients treated with brenetafusp monotherapy, although most cases were Grade 1 and manageable.
• The median progression-free survival (PFS) for brenetafusp monotherapy was 3.3 months, which may be considered modest.
• The overall survival (OS) data for the monotherapy arm is still maturing.

Risks

• The clinical trial data is still early, and further studies are needed to confirm the efficacy and safety of brenetafusp.
• The company faces competition in the development of cancer immunotherapies.
• The company's ability to obtain regulatory approval and commercialize brenetafusp is subject to various risks and uncertainties.
• The company's financial position and ability to fund ongoing and planned clinical trials could be impacted by worsening macroeconomic conditions.

Future Outlook

The company plans to investigate brenetafusp in earlier-line patients and expand the combinations being studied, including with checkpoint inhibitors, chemotherapy, and tebentafusp. They are also continuing dose escalation in additional solid tumors.

Management Comments

• David Berman, Head of Research and Development, stated that they see the hallmarks of ImmTAC clinical activity in the Phase 1 data, increasing their confidence in the potential for brenetafusp in ovarian cancer.
• Dr. Claire Friedman, Gynecologic Medical Oncologist, noted that the data offers proof of concept that patients with advanced, platinum-resistant ovarian cancer can benefit from brenetafusp, alone or in combination with chemotherapy.

Industry Context

This announcement is significant as it provides further evidence of the potential of ImmTAC therapies in treating solid tumors, particularly in areas with high unmet need like ovarian cancer. The identification of T cell fitness as a biomarker could also be a key development in personalizing cancer treatment.

Comparison to Industry Standards

• Historical chemotherapy efficacy data in heavily pre-treated platinum-resistant ovarian cancer patients shows response rates less than 10%, with disease control rates typically around 40-50%.
• The brenetafusp monotherapy showed a 6.5% RECIST response rate and 58% disease control rate, which is comparable to or better than historical chemotherapy data.
• The combination of brenetafusp with chemotherapy showed a 23% RECIST response rate and 69% disease control rate, significantly exceeding historical chemotherapy benchmarks.
• The T cell fitness biomarker approach is novel and could potentially improve patient selection and treatment outcomes compared to standard approaches.

Stakeholder Impact

• Shareholders may view the positive clinical data as a positive development for the company.
• Patients with ovarian cancer may benefit from the development of new treatment options.
• Employees may be motivated by the progress of the company's research and development efforts.
• The company's success could lead to increased revenue and growth.

Next Steps

• The company will continue to enroll patients into expansion arms in ovarian, NSCLC, and endometrial cancers.
• Dose escalation will continue in additional solid tumors.
• The company plans to investigate combination arms with standards-of-care, including checkpoint inhibitors, chemotherapy, and tebentafusp.
• The company will further investigate brenetafusp in earlier-line patients.

Key Dates

Keywords

brenetafusp, ovarian cancer, ImmTAC, immunotherapy, T cell fitness, KIMMTRAK, bispecific therapy, PRAME, clinical trial, metastatic uveal melanoma, ctDNA, chemotherapy